Alexza Pharmaceuticals is focused on the research, development, and commercialization of novel, proprietary products for the acute treatment of medical conditions. Alexza's products and development pipeline are based on the Staccato One Breath Technology - OBT system, a handheld inhaler designed to deliver a pure drug aerosol to the deep lung, providing rapid systemic delivery and therapeutic onset in a simple, non-invasive manner.
Services
Integrity is a key value at Ferrer and its affiliates, and is a pillar of our mission to advance the well-being of society. Ferrer's ethical code, which you can consult below, establishes principles of action, for Ferrer and the companies it works with, that go beyond mere compliance with regulations.
For the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. Full prescribing information, including boxed warning, at ADASUVE.com or the EMA website. To discuss partnership and licensing opportunities, please contact our Business Development Group. Alexza has a number of programs in active development in addition to our approved commercial product ADASUVE (loxapine) inhalation powder.
Through licensing relationships, research collaborations and strategic alliances that complement and extend the Staccato technology, Alexza is interested in collaborations that have the potential to create superior products and improve patients' lives. For the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.
Alexza is always looking for partners in innovation. We are looking for developmental and commercial partners for our pipeline programs, and we welcome partnering your molecules that could benefit from Staccato One Breath Technology - OBT. We are interested in developing products across different therapeutic areas where speed of onset and non-invasive delivery make a difference.
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. The company is continuously working to advance science and embrace new knowledge.
